CA-OMNICELL
Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and supply chain solutions for health systems, today announced its intent to enter a new partnership with Guy’s and St Thomas’ NHS Foundation Trust, London to develop technology-enabled inventory optimization and intelligence services.
As part of a £10.5 million capital investment, the South East London Integrated Care System (ICS) will expand the deployment of Omnicell automation systems across six acute hospital sites. This also includes the opportunity for Omnicell and the Trust to launch a European-based technology-enabled intelligence center with the aim to deliver advanced analytics to manage supplies and medications. Combined with the expansion of Omnicell automated dispensing systems across the South East London hospitals, it is expected that this technology-enabled intelligence center will provide a high level of visibility and actionable insights for the South East London Integrated Care System to improve efficiency and patient safety.
The Integrated Care System includes two of the UK’s biggest hospital trusts, Guy’s and St Thomas’ NHS Foundation Trust and Kings College Hospital NHS Foundation Trust, as well as Lewisham and Greenwich NHS Trust. These Trusts are already using a mix of Omnicell’s XT supply and medication dispensing systems to manage clinical inventory and medications. The ICS successfully secured capital funding from the Department of Health Wave IV Estate Transformation Fund to undertake a regional supply chain transformation program.
By choosing Omnicell as its sole Inventory Management Solution, the Integrated Care System will be able to deliver consistency of practice and openly share data through a single instance based in the cloud. These systems, coupled with the expected technology-enabled intelligence centre based at Guy’s and St Thomas’, aim to provide total visibility of all medication and clinical inventory across the region. The solution will leverage the latest AI tools to provide real-time analytic support and system optimization. This will help reduce the risk of dispensing errors and help deliver the right medication, in the right place, at the right time.
Omnicell’s cloud-based intelligence, automation, and technology-enabled services are helping health systems across the globe to:
- support patient safety
- drive efficiencies
- reduce unnecessary and costly wastage
- allow healthcare professionals to increase their time for face-to-face patient care.
David Lawson, Chief Procurement Officer for Guy’s and St Thomas’, said: “We are delighted to join with Omnicell to bring this cutting-edge solution to the UK. The Trust has successfully deployed Omnicell systems for supplies and medication for over 10 years and the opportunity of this new intelligence offering alongside the expansion of Omnicell systems across South East London represents the next chapter in a successful long term partnership with Omnicell. Through this collaboration, South East London hopes to develop new AI tools to reduce variation between hospital sites and optimize system performance to allow for improved patient outcomes and operational efficiency at a regional level.”
Sara Dalmasso, vice president and general manager, International, at Omnicell said: “Expanding technology-enabled services and intelligence solutions reflects our ambition to deploy advanced analytic and optimization tools to support health systems across Europe. This new partnership with Guy’s and St Thomas’ also demonstrates that Omnicell is quickly becoming the go-to provider for regional medication and supply management solutions across the UK. We are hugely excited to be offered another opportunity to work with a likeminded partner who wants to reshape how automated inventory and medical supply management systems are viewed in the NHS and the wider European market. We share a goal of improving healthcare and patient safety, and I’m looking forward to working with Guy’s and St Thomas’ and South East London to support our joint vision.”
About Guy’s and St Thomas’ and South East London Integrated Care System
Guy’s and St Thomas’ provides 2.6 million patient contacts in acute and specialist hospital services and community services every year. As one of the biggest NHS trusts in the UK, with an annual turnover of almost £1.7 billion, we employ around 18,000 staff. To learn more, visit: www.guysandstthomas.nhs.uk
South East London Integrated Care System brings together local health and care organisations and local councils to re-design care and improve population health through shared leadership and collective action. It covers six London boroughs, Bexley, Bromley, Greenwich, Lambeth, Lewisham and Southwark, with 1.9 million patients. Priorities include reducing costs through provider collaboration and changing the way they work together to deliver transformation. To learn more, visit: https://www.ourhealthiersel.nhs.uk/
About Omnicell
Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 50,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit www.omnicell.com .
OMCL-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005125/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom